Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
Tokyo-based biotech Oncolys BioPharma aims to position its oncolytic virus therapy telomelysin as a first-line treatment for esophageal cancer in the long term, President and CEO Yasuo Urata said in an interview with Jiho. Telomelysin, otherwise known as OBP-301, is…
To read the full story
Related Article
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Oncolys’ Oncolytic Virus Telomelysin Gets Orphan Status in Japan
December 15, 2025
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
BUSINESS
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…